Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of ALXN1840 on Bupropion PK in Healthy Participants
NCT04526210Phase 1Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Oct 2020
- Primary completion
- May 2021
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of atn-224 in Wilson disease (WD), sponsored by Alexion Pharmaceuticals. Primary endpoints: Maximum Observed Plasma Concentration (Cmax) of Bupropion, Area Under the Plasma Concentration Versus Time Curve From Time 0 to Last Quantifiable Concentration (AUCt) of Bupropion and 1 more. Started Oct 2020; status: completed.
02
Drugs
atn-224
03
Conditions
Wilson disease (WD)
Beyond the preview
Go deeper on NCT04526210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04526210.